Eagle Pharmaceuticals, Inc. · OTC:EGRX

Eagle Pharmaceuticals — J.P. Morgan Healthcare Conference January 2023

14 slides from Eagle Pharmaceuticals's conference presentation, Jan 9, 2023

1. Slide 1: Company Overview J.P. Morgan Healthcare Conference January 2023

   © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 1 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Company Overview J.P. Morgan Healthcare Conference January 2023

2. Slide 2: Forward-Looking Statements

   © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 2 Forward - Looking Statements This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, and other securities law . Forward - looking statements are statem

3. Slide 3: Financial Position as it Transforms into a Diversified Pharmaceutical Company

   © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 3 Eagle Pharmaceuticals Financial Position as it Transforms into a Diversified Pharmaceutical Company *As of 9/30/22; takes into account cash consideration paid for Acacia Pharma Group plc ("Acacia") acquisition **As of 11/2/22 Strong Financial

4. Slide 4: Key Financial Metrics: Earnings Timeline – Actuals and Estimates

   © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 4 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Eagle Pharmaceuticals Key Financial Metrics 4 Earnings Timeline – Actuals and Estimates 2020 2021 LTM 9.30.22* 2023E Range** Adjusted EBITDA (US$M) $64.7 $43.5 $125.6 $74.0 - $80.0 Non -

5. Slide 5: U.S. Bendamustine Revenue as Share of EGRX Total

   © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 5 5 U.S. Bendamustine Revenue as Share of EGRX Total 2023 Expectations 21% 16% 15% 8% 19% 20% 54% 68% 79% 84% 85% 92% 81% 80% 46% 32% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2016 2017 2018 2019 2020 2021 LTM 9.30.22 2023E Other Revenue Sour

6. Slide 6: Further Improving Margin and Contribution for Key Products

   © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 6 Further Improving Margin and Contribution for Key Products • BENDEKA, BELRAPZO & TREAKISYM • 10% of profits • $12.5M in LTM 9.30.2022 4Q 2022: Expiring Development Partner Royalty on Bendamustine Franchise Profits • Includes elimination of 25

7. Slide 7: Key Financial Metrics: Earnings Timeline – Actuals and Estimates

   © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 7 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Eagle Pharmaceuticals Key Financial Metrics 7 Earnings Timeline – Actuals and Estimates 2020 2021 LTM 9.30.22* 2023E Range** Adjusted EBITDA (US$M) $64.7 $43.5 $125.6 $74.0 - $80.0 Non -

8. Slide 8: Eagle Product Portfolio Is Supported by Commercial Team

   © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 8 Eagle Product Portfolio Is Supported by 75 - Person Commercial Team For treatment of malignant hyperthermia RYANODEX ® To increase blood pressure in adults with vasodilatory shock Vasopressin For prevention of PONV*, and treatment of PONV in

9. Slide 9: Product Candidates and Pipeline Opportunities

   © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 9 Eagle Pharmaceuticals Product Candidates and Pipeline Opportunities Using cash flow from legacy products to fund R&D for branded pipeline. Additional cash and balance sheet equity available to acquire existing marketed assets. Landiolol 1 CAL

10. Slide 10: Thank You!

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 10 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Thank You!

11. Slide 11: Appendix

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 11 11 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Appendix

12. Slide 12: Non-GAAP Financial Performance Measures

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 12 Non - GAAP Financial Performance Measures I n addition to financial information prepared in accordance with U.S. GAAP, this presentation also contains adjusted EBITDA an d a djusted non - GAAP earnings per share attributable to Eagle and pro

13. Slide 13: Reconciliation of GAAP to Adjusted Non-GAAP Net Income

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 13 13 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 2021 2020 Net (loss) income - GAAP (8,627)$ 11,989$ Adjustments: Cost of product revenues: Amortization expense 1,578 1,046 Research and development: Stock-based compensation expense

14. Slide 14: Reconciliation of GAAP to Adjusted Non-GAAP EBITDA

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 14 14 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 2022 Net (loss) income - GAAP 18,850$ Add back: Interest expense, net of interest income 3,186 Income tax provision 24,731 Depreciation and amortization expense 10,154 Add back: Stoc

Eagle Pharmaceuticals — J.P. Morgan Healthcare Conference January 2023 on 6ix